Generex Subsidiary Antigen Express Receives Patent in China for Its Ii-Key Peptide Vaccine Technology
Company in Active Discussions with Several Large Pharmaceutical Companies for Potential Joint Venture/Licensing Partnerships for Its Cancer Vaccine Technology Platform
Generex Biotechnology Corporation announced that it has received notice of issuance of a patent on its Ii-Key peptide technology in China. This expands a solid intellectual property estate that includes both broad claims covering its technology as well as specific Ii-Key-containing drug development compounds. Additionally, management is actively seeking potential joint venture/licensing partnerships for its peptide cancer vaccine technology platform and is in active discussions with several large pharmaceutical companies.
The Company recently reported interim results from a Phase II trial of an Ii-Key modified peptide vaccine for patients treated for breast cancer who are at high risk of relapse. While there was a 7% relapse rate in the control arm there were no relapses in the Ii-Key peptide arm (AE37) when analyzed at the 13-month time point. A review article co-authored by Eric von Hofe, Ph.D., President of Antigen Express entitled ‘A New Era in Anticancer Peptide Vaccines’, appeared in the journal Cancer, published by the American Cancer Society.
Other news from the department research and development
